We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


BrainStorm Cell Therapeutics and Rutgers University Join Forces to Identify a Cure for Spinal Cord Injuries via Stem-Cell Research

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BrainStorm Cell Therapeutics and Rutgers University Join Forces to Identify a Cure for Spinal Cord Injuries via Stem-Cell Research"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

BrainStorm Cell Therapeutics Inc. has announced that the Company has expanded its collaboration with Rutgers University in an effort to cure spinal cord injuries through BrainStorm’s adult stem cell research. The Spinal Cord Injury Project is the first focus of the W. M. Keck Center for Collaborative Neuroscience at Rutgers University.

Spinal cord injuries cause damage to the fiber tracts that carry sensation and motor signals to and from the brain. Such injuries also damage the central part of the spine, causing segmental losses of interneurons and motor neurons.

The study, combined with BrainStorm’s differentiation process, uses stem cells derived from human bone marrow that are expanded and induced to secrete neurotrophic factors. Preliminary evidence has indicated that transplantation of differentiated (but not non-differentiated) human bone marrow derived stem cells improved motor behavior of subjects used in animal studies as measured by motor and walking analysis.

“We are excited to embark on this project with such a highly respected U.S. educational institution,” said Chaim Lebovits, President of BrainStorm Cell Therapeutics. “Our preliminary results provide a strong validation for continuing our collaborative efforts to confirm these findings through additional testing that could, with G-D’s help, potentially lead to a new strategy for cell therapy to cure spinal cord injuries.”